RECRUITING

Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.

Official Title

Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss

Quick Facts

Study Start:2025-02
Study Completion:2028-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06734273

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult 18 to 65 years of age
  2. * Body Mass Index \>35 with comorbidity of Type 2 Diabetes and/or Hypertension and/or Hyperlipidemia and/or Obstructive Sleep Apnea OR Body Mass Index \>40 with or without comorbidity
  3. * Undergoing primary sleeve gastrectomy
  1. * Prior metabolic and bariatric surgery
  2. * Prior use of GLP-1 agonist
  3. * Prior history of pancreatitis
  4. * Personal/family history of medullary thyroid cancer or MEN type 2
  5. * Secondary cause of obesity
  6. * Any eating disorder
  7. * Pregnancy/lactation
  8. * History of acute coronary syndrome or myocardial infarction
  9. * History of stroke
  10. * Hepatic dysfunction: AST/ALT \>3 ULN
  11. * Renal dysfunction eGFR\<45ml/min/1.73m2
  12. * Active malignancy
  13. * History of diabetic retinopathy
  14. * History of gastroparesis

Contacts and Locations

Study Contact

Research Administrator
CONTACT
312-942-5500
anna_t_alecci@rush.edu

Principal Investigator

Nicholas Skertich, MD
PRINCIPAL_INVESTIGATOR
Rush University Medical Center

Study Locations (Sites)

Rush University Medical Center
Chicago, Illinois, 60612
United States

Collaborators and Investigators

Sponsor: Nicholas Skertich

  • Nicholas Skertich, MD, PRINCIPAL_INVESTIGATOR, Rush University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02
Study Completion Date2028-02

Study Record Updates

Study Start Date2025-02
Study Completion Date2028-02

Terms related to this study

Additional Relevant MeSH Terms

  • Obesity and Obesity-related Medical Conditions